Span Divergent Ltd

Span Divergent is rated Sell by MarketsMOJO. This rating was last updated on 11 Nov 2025, reflecting a shift from a previous Strong Sell grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Span Divergent Ltd witnessed a pronounced sell-off on 20 Nov 2025, with the stock hitting its lower circuit and registering a day loss of 5.00%, significantly underperforming the Sensex which gained 0.66% on the same day. The absence of buyers and the presence of only sell orders signal distress selling, marking a sharp reversal after eight consecutive days of gains.

Span Divergent Ltd has demonstrated extraordinary buying interest today, registering a 4.97% gain with exclusively buy orders in the queue. This rare market phenomenon highlights a potential multi-day upper circuit scenario, underscoring strong investor enthusiasm in the Pharmaceuticals & Biotechnology sector.

Span Divergent Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, is experiencing notable buying activity, with the stock gaining significantly today. It has shown strong performance over the past week and month, trading above key moving averages, despite a year-to-date decline. Long-term growth remains impressive.

Span Divergent Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, is experiencing heightened buying activity, significantly outperforming the broader market. The stock has shown consistent gains over the past week and is trading above key moving averages, indicating a positive shift in market sentiment despite earlier year-to-date challenges.

Span Divergent Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, is experiencing notable buying activity, with a recent surge in stock price. The company has shown resilience, achieving consecutive gains over the past week, indicating a shift in market sentiment and attracting investor interest despite earlier year-to-date challenges.

Span Divergent Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, is experiencing notable buying activity, with a 4.97% increase today. The stock has risen 15.37% over the past week and has shown a total return of 21.42% in the last four days, despite a negative year-to-date performance.

Span Divergent Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, is experiencing notable buying activity, with a recent three-day gain of 15.67%. Despite a challenging month, the stock has shown a significant increase over the past three months, outperforming the broader market indices.

Span Divergent, a microcap in the Pharmaceuticals & Biotechnology sector, has recently experienced an evaluation adjustment reflecting changes in its technical indicators. The stock's technical trend has shifted, presenting a mixed outlook across various metrics, while the company has faced challenges in performance over the past year.

Span Divergent Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, is experiencing notable buying activity, with recent gains contrasting the broader market's decline. Despite a challenging month, the stock shows a positive three-month trend and remains above key moving averages, reflecting some resilience amid sector gains.

Span Divergent Ltd., a micro-cap pharmaceutical diagnostics company with a market capitalisation of ₹12.00 crores, reported a consolidated net loss of ₹0.13 crores for Q2 FY26, deepening its loss trajectory despite a dramatic 173.21% year-on-year surge in net sales to ₹7.65 crores. The stock rallied 4.99% on November 11, 2025, trading at ₹23.98, though it remains 47.06% below its 52-week high of ₹45.30, reflecting investor scepticism about the company's ability to translate revenue growth into sustainable profitability.

Span Divergent Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, is experiencing notable buying activity today, marking a trend reversal after 20 days of decline. Despite recent losses, the stock has outperformed the Sensex over the past three months, indicating potential shifts in market sentiment.

Span Divergent Ltd, a microcap in the Pharmaceuticals & Biotechnology sector, is experiencing notable buying activity despite recent declines. The stock has faced significant drops over various timeframes, yet it has outperformed the Sensex over three and five years. Current trading shows erratic patterns and is below key moving averages.